



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 1 312 679 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)
INID code(s) 84

(51) Int Cl.7: **C12N 15/863**, C12N 15/53,
C12N 15/54, C12N 5/10,
A61K 39/285

(48) Corrigendum issued on:
23.11.2005 Bulletin 2005/47

(45) Date of publication and mention
of the grant of the patent:
07.09.2005 Bulletin 2005/36

(21) Application number: **03001379.1**

(22) Date of filing: **03.07.1996**

(54) **Recombinant MVA virus, and the use thereof**

Rekombinante MVA Viren und deren Verwendung

Virus MVA recombinants et leur utilisation

(84) Designated Contracting States:
AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC
NL PT SE
Designated Extension States:
AL LT LV SI

(30) Priority: **04.07.1995 DK 78295**

(43) Date of publication of application:
21.05.2003 Bulletin 2003/21

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
96925654.4 / 0 836 648

(73) Proprietor: **GSF Forschungszentrum für Umwelt
und Gesundheit GMBH**
85764 Oberschleissheim (DE)

(72) Inventors:
• **Sutter, Gerd**
80802 München (DE)
• **Ohlmann, Marion**
81927 München (DE)
• **Erfle, Volker**
81679 München (DE)

(74) Representative: **Pielken, Petra**
Bavarian Nordic GmbH,
Fraunhoferstrasse 18 b
82152 Martinsried (DE)

(56) References cited:
EP-A- 0 324 350

- **WÖLFEL T ET AL: "TWO TYROSINASE NONAPEPTIDES RECOGNIZED ON HLA-A2 MELANOMAS BY AUTOLOGOUS CYTOLYTIC T LYMPHOCYTES" EUROPEAN JOURNAL OF IMMUNOLOGY, WEINHEIM, DE, vol. 24, 1994, pages 759-764, XP000571867 ISSN: 0014-2980**
- **JIMBOW K ET AL: "COORDINATED MRNA AND PROTEIN EXPRESSION OF HUMAN LAMP-1 IN INDUCTION OF MELANOGENESIS AFTER UV-B EXPOSURE AND CO-TRANSFECTION OF HUMAN TYROSINASE AND TRP-1 CDNAS" PIGMENT CELL RESEARCH, COPENHAGEN, DK, vol. 7, no. 5, October 1994 (1994-10), pages 311-319, XP000953012 ISSN: 0906-9305**
- **G.SUTTER ET AL.: "A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus" VACCINE, vol. 12, no. 11, August 1994 (1994-08), pages 1032-1040, XP002019163 GUILDFORD GB**

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 1 312 679 B8

- DREXLER I ET AL: "Modified vaccinia virus Ankara for delivery of human tyrosinase as melanoma-associated antigen: Induction of tyrosinase- and melanoma-specific human leukocyte antigen A*0201-restricted cytotoxic T-cells in vitro and in vivo" CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 59, 1 October 1999 (1999-10-01), pages 4955-4963, XP002185047 ISSN: 0008-5472